c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

PubWeight™: 1.61‹?› | Rank: Top 4%

🔗 View Article (PMC 3181384)

Published in Hepatology on July 19, 2011

Authors

Hanning You1, Wei Ding, Hien Dang, Yixing Jiang, C Bart Rountree

Author Affiliations

1: Department of Pediatrics and Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA.

Articles citing this

Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39

Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell (2012) 1.27

Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology (2012) 1.21

Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2012) 1.17

Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer (2011) 1.09

Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One (2013) 1.02

Epithelial to Mesenchymal Transition in a Clinical Perspective. J Oncol (2015) 0.99

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther (2014) 0.97

Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol (2014) 0.96

Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer (2012) 0.94

Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther (2014) 0.91

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology (2014) 0.90

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget (2016) 0.88

MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets. BMC Cancer (2015) 0.87

Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One (2012) 0.86

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep (2013) 0.85

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol (2015) 0.84

MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET. Oncol Lett (2014) 0.84

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS One (2015) 0.84

Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol (2015) 0.84

A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers. PLoS One (2012) 0.84

Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.83

Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83

Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget (2014) 0.82

Disturbance of Ca2+ homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J Biol Chem (2012) 0.82

The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem (2012) 0.82

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget (2015) 0.82

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel) (2014) 0.82

Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma. BMC Cancer (2015) 0.81

Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One (2012) 0.81

MRC-5 fibroblast-conditioned medium influences multiple pathways regulating invasion, migration, proliferation, and apoptosis in hepatocellular carcinoma. J Transl Med (2015) 0.80

Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther (2015) 0.79

Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol (2017) 0.79

Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One (2015) 0.78

Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One (2014) 0.78

Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol (2014) 0.78

Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells. Int J Clin Exp Pathol (2015) 0.78

Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res (2015) 0.77

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J Exp Clin Cancer Res (2016) 0.77

The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma. Cancer Biol Ther (2012) 0.77

Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2. Oncotarget (2016) 0.77

Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist (2014) 0.76

Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma. Onco Targets Ther (2017) 0.75

Damnacanthal, a noni anthraquinone, inhibits c-Met and is a potent antitumor compound against Hep G2 human hepatocellular carcinoma cells. Sci Rep (2015) 0.75

Anti-fibro-hepatocarcinogenic Chinese herbal medicines: A mechanistic overview. J Intercult Ethnopharmacol (2016) 0.75

Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncoimmunology (2016) 0.75

Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma. PLoS One (2012) 0.75

An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib. Korean J Hepatobiliary Pancreat Surg (2015) 0.75

A robust screening method for dietary agents that activate tumour-suppressor microRNAs. Sci Rep (2015) 0.75

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met. J Cancer (2017) 0.75

The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells. J Cell Commun Signal (2016) 0.75

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases (2015) 0.75

Articles cited by this

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

Hepatocellular carcinoma. Lancet (2003) 22.54

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81

A progression puzzle. Nature (2002) 9.56

Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95

Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89

Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol (2002) 3.83

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47

Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42

Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01

Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92

c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81

High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut (2010) 2.58

Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol (2001) 2.32

Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells (2005) 1.96

The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A (1998) 1.76

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett (2008) 1.71

The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.71

Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology (2010) 1.63

Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology (2009) 1.56

Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43

CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology (2009) 1.40

Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells (2009) 1.33

The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology (2001) 1.27

Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology (1997) 1.14

Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology (1997) 1.12

Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene (1995) 1.05

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology (2010) 1.05

Articles by these authors

Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood (2009) 2.50

Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol Cell Biol (2006) 2.12

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene (2003) 1.79

Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2004) 1.73

Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Fertil Steril (2003) 1.67

Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis (2006) 1.64

Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology (2010) 1.63

Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol (2004) 1.62

Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood (2009) 1.61

SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood (2008) 1.61

Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60

Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab (2006) 1.54

Concern Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One (2013) 1.49

Oocyte vitrification technology has made egg-sharing donation easier in China. Reprod Biomed Online (2011) 1.45

Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis (2013) 1.40

CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology (2009) 1.40

Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chem Res Toxicol (2004) 1.37

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34

Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells (2009) 1.33

Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via beta-catenin activation. Hepatology (2007) 1.30

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol (2008) 1.29

Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia. Am J Respir Cell Mol Biol (2006) 1.28

Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I). J Virol (2002) 1.27

Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology (2010) 1.25

Microarray profile of differentially expressed genes in a monkey model of allergic asthma. Genome Biol (2002) 1.20

Langerhans' cell density and degree of keratinization in foreskins of Chinese preschool boys and adults. Int Urol Nephrol (2009) 1.17

Structure of the Leanyer orthobunyavirus nucleoprotein-RNA complex reveals unique architecture for RNA encapsidation. Proc Natl Acad Sci U S A (2013) 1.17

A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated T cell activation. J Biol Chem (2003) 1.16

Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol (2011) 1.15

Characterization of the azinomycin B biosynthetic gene cluster revealing a different iterative type I polyketide synthase for naphthoate biosynthesis. Chem Biol (2008) 1.13

Comparative study of unilateral and bilateral pedicle screw fixation in posterior lumbar interbody fusion. Orthopedics (2012) 1.12

The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol (2008) 1.11

Unilateral versus bilateral instrumented transforaminal lumbar interbody fusion in two-level degenerative lumbar disorders: a prospective randomised study. Int Orthop (2013) 1.11

Naked2 acts as a cargo recognition and targeting protein to ensure proper delivery and fusion of TGF-alpha containing exocytic vesicles at the lower lateral membrane of polarized MDCK cells. Mol Biol Cell (2007) 1.10

Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer (2011) 1.09

HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB. J Biol Chem (2009) 1.08

Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol (2008) 1.08

Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. J Immunol Methods (2004) 1.07

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood (2002) 1.07

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs (2006) 1.06

Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol (2009) 1.05

The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim (2003) 1.05

A review of Omics research in acupuncture: the relevance and future prospects for understanding the nature of meridians and acupoints. J Ethnopharmacol (2012) 1.04

Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther (2005) 1.04

Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. J Biol Chem (2006) 1.03

MiR-126-3p regulates progesterone receptors and involves development and lactation of mouse mammary gland. Mol Cell Biochem (2011) 1.03

Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut (2010) 1.02

Dual actions involved in arsenite-induced oxidative DNA damage. Chem Res Toxicol (2008) 1.02

Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod (2007) 1.00

[Longitudinal investigation and experimental studies on thelaziasis and the intermediate host of Thelazia callipaeda in Guanghua county of Hubei province]. Zhonghua Liu Xing Bing Xue Za Zhi (2003) 1.00

Characterization of the saframycin A gene cluster from Streptomyces lavendulae NRRL 11002 revealing a nonribosomal peptide synthetase system for assembling the unusual tetrapeptidyl skeleton in an iterative manner. J Bacteriol (2007) 0.99

Structure and dynamics of the homodimeric dynein light chain km23. J Mol Biol (2005) 0.99

Structure of severe fever with thrombocytopenia syndrome virus nucleocapsid protein in complex with suramin reveals therapeutic potential. J Virol (2013) 0.99

Exploring practice characteristics and research priorities of practitioners of traditional acupuncture in China and the EU-A survey. J Ethnopharmacol (2012) 0.99

Genetic diversity and phylogeny of antagonistic bacteria against Phytophthora nicotianae isolated from tobacco rhizosphere. Int J Mol Sci (2011) 0.99

Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma (2009) 0.98

Online feature selection with streaming features. IEEE Trans Pattern Anal Mach Intell (2013) 0.98

A novel transforming growth factor-beta receptor-interacting protein that is also a light chain of the motor protein dynein. Mol Biol Cell (2002) 0.98

Leptomeningeal carcinomatosis as the only manifestation of disease in recurrent gastroesophageal cancers. Gastrointest Cancer Res (2011) 0.97

A multi-dataset data-collection strategy produces better diffraction data. Acta Crystallogr A (2011) 0.94

Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci (2004) 0.94

Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother (2002) 0.94

Cyr61/CCN1 is regulated by Wnt/β-catenin signaling and plays an important role in the progression of hepatocellular carcinoma. PLoS One (2012) 0.94

Fibroblast growth factor receptor-mediated activation of AKT-β-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts and hepatic tumor initiating stem cells. PLoS One (2012) 0.94

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93

Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) (2011) 0.93

HCV genotyping using statistical classification approach. J Biomed Sci (2009) 0.92

Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-beta signaling pathway. J Biol Chem (2007) 0.92

S-SAD phasing study of death receptor 6 and its solution conformation revealed by SAXS. Acta Crystallogr D Biol Crystallogr (2012) 0.91

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica (2013) 0.91

Silver nanoparticle-induced mutations and oxidative stress in mouse lymphoma cells. Environ Mol Mutagen (2012) 0.91

Primary pulmonary synovial sarcoma, a rare primary lung neoplasm: two case reports and review of the current literature. Respirology (2008) 0.91

Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem (2005) 0.90

c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. Mol Carcinog (2006) 0.90

Role of iron and sodium citrate in animal protein-free CHO cell culture medium on cell growth and monoclonal antibody production. Biotechnol Prog (2010) 0.90

Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int (2013) 0.90

Ultrathin, high-efficiency, broad-band, omni-acceptance, organic solar cells enhanced by plasmonic cavity with subwavelength hole array. Opt Express (2013) 0.90

Analysis of the ERK1,2 transcriptome in mammary epithelial cells. Biochem J (2004) 0.90

Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis. Cell Physiol Biochem (2015) 0.89

Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest (2014) 0.89

Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci Lett (2004) 0.89

Computational analysis of composite regulatory elements. Mamm Genome (2002) 0.89

Genome wide in silico SNP-tumor association analysis. BMC Cancer (2004) 0.89

Calpain: a molecule to induce AIF-mediated necroptosis in RGC-5 following elevated hydrostatic pressure. BMC Neurosci (2014) 0.88

Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci (2011) 0.88

Multidisciplinary management of early and locally advanced esophageal cancer. J Clin Gastroenterol (2011) 0.88

AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol (2013) 0.88

Structural basis for termination of AIM2-mediated signaling by p202. Cell Res (2013) 0.88

Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology (2006) 0.88

Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol (2002) 0.88

The effect of the insecticide dichlorvos on esterase activity extracted from the psocids, Liposcelis bostrychophila and L. entomophila. J Insect Sci (2004) 0.87

Quantitative T2 mapping to characterize the process of intervertebral disc degeneration in a rabbit model. BMC Musculoskelet Disord (2013) 0.87

Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer (2014) 0.87

Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci (2014) 0.87